Stay of FSS Procurement Requires Prompt Action
Client Alert | less than 1 min read | 11.09.05
In Systems Plus, Inc. v. U.S. (Oct. 27, 2005), the Court of Federal Claims held that a Federal Supply Schedule procurement for a blanket purchase agreement conducted as a commercial item buy under FAR part 12, rather than part 15, does not require that the agency provide a debriefing to a disappointed bidder. As a result, the automatic statutory stay upon a GAO protest runs only for 10 days from contract award and not also for 5 days from any discretionary debriefing in such situations.
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
